Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Against pulmonary fibrosis

07.03.2006


The biotech companies Digna Biotech and Biotherapix have signed an agreement to jointly apply their patented products towards the development of a treatment for pulmonary fibrosis. Digna Biotech is the commercial entity responsible for developing the intellectual property (patents) generated by the CIMA of the University of Navarra in its preclinical, clinical and commercial research.

The focal points of this agreement are the M3 protein owned by Biotherapix and the p17 peptide from Digna Biotech. It is hoped that these two compounds can work in common, taking advantage of the chemokyne inhibiting activity of M3 and the specific TGF-beta1 inhibiting activity of p17. Both TGF-beta1 as well as the chemokynes are key molecules in various inflammatory and degenerative processes. The researchers believe that the combined action of M3 and p17 will allow the development of a viable therapeutic alternative for treating pulmonary fibrosis.

The necessary studies for the development of the treatment us the p17 peptide and the M3 protein will be preferentially performed in centers of the University of Navarra: the CIMA, the University Hospital and the CIFA (Center for Research in Applied Pharmacobiology).



Combination of the p17 peptide and the M3 protein

The causes of pulmonary fibrosis are poorly known; this disease is characterized by an abnormal accumulation of collagen fibers in the lung, which causes structural deterioration. This deterioration causes progressive scarring in the lungs, which impedes the uptake of oxygen into the bloodstream, and thus impedes respiration. The European health authorities currently consider that pulmonary fibrosis is a rare or uncommon disease, with a prevalence of from 13 cases (in men) to 20 cases (in women) per 100,000 persons.

There do not currently exist effective treatments for this disease. The current treatments are based on the administration of oxygen and anti-inflammatories (glucocorticoids), some associated with immunosuppression and others not. These therapies have had limited success in reduction the progress of the fibrosis, and a contribute little to improving the quality of life of those affected.

The p17 peptide has demonstrated its effectiveness in the animal model which best reproduces pulmonary fibrosis. Currently, research is underway to confirm these findings with other models, and to begin toxicological studies. M3, on the other hand, is a protein of viral origin which has demonstrated its neutralizing effect against a wide set of molecules from the chemokyne family. Biotherapix is researching the use of derivatives of this molecule in order to slow certain inflammatory processes in which chemokynes play a key role. The M3 protein has shown advantages over other biological therapeutic molecules, such as its inhibiting activity against multiple chemokynes, as well as its low toxicity.

Irati Kortabitarte | alfa
Further information:
http://www.basqueresearch.com/berria_irakurri.asp?Gelaxka=1_1&hizk=I&Berri_Kod=911

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>